BusinessCellular Biomedicine Group Reports First Quarter 2018 Financial Results and Highlights Operational ProgressBy Nasdaq OMXMay 8, 2018, 10:01 AM UTC
BusinessCellular Biomedicine Group (CBMG) Announces Annual Meeting of StockholdersBy Nasdaq OMXMar 23, 2018, 11:00 AM UTC
BusinessCellular Biomedicine Group Announces Positive 48-Week Clinical Data of AlloJoin™ Human Adipose-Derived Mesenchymal Progenitor Cell (haMPC) Knee Osteoarthritis (KOA) China Phase I TrialBy Nasdaq OMXMar 16, 2018, 11:00 AM UTC
BusinessCellular Biomedicine Group Announces Upcoming Presentation to Release 48-Week Data from Phase I Clinical Trial for AlloJoin™ Off-the-Shelf Allogeneic Stem Cell Therapy for Knee OsteoarthritisBy Nasdaq OMXMar 14, 2018, 11:30 AM UTC
BusinessCellular Biomedicine Group Reports Full-Year 2017 Financial Results and Recent Operational ProgressBy Nasdaq OMXMar 6, 2018, 2:27 PM UTC
BusinessCellular Biomedicine Group Invited to Present a Keynote Speech at Phar-East Asia Pharma & Biotech FestivalBy Nasdaq OMXMar 1, 2018, 2:15 PM UTC
BusinessCellular Biomedicine Group Announces $30.6 million Investment from Sailing Capital Overseas Investment Ltd.By Nasdaq OMXFeb 5, 2018, 1:18 PM UTC
BusinessCBMG Accelerates Cell Therapy Manufacturing with GE Healthcare’s New Start-to-Finish SolutionBy Nasdaq OMXJan 20, 2018, 1:43 AM UTC
